"Generic 50 mg atenolol, blood pressure bottom number."

By: Jennifer Lynn Garst, MD

  • Professor of Medicine
  • Member of the Duke Cancer Institute


Family and psychoeducational interventions may be particularly useful in reaching diverse older adults hypertension diabetes cheap atenolol 50 mg. As such blood pressure 9860 purchase 50 mg atenolol, a public health and clinical priority in optimizing care for older adults is identifying psychosocial treatments that are effective across diverse racial blood pressure time of day 50 mg atenolol visa, ethnic blood pressure in dogs order atenolol 100mg online, and socioeconomic groups; can be carried out in general medical settings (such as problem-solving therapy; Unutzer et al. The Need for a Clinical Practice Guideline and Decisions about Scope and Goals of the Clinical Practice Guideline Available treatment guidelines for the problem. Given the evidence that depression is a disorder whose cost and burden justify extensive efforts at intervention, providers need access to information that will help guide intervention. While there is now a substantial body of research literature examining a broad range of approaches to assessment and treatment (including psychotherapeutic, pharmacologic, and other interventional approaches), studies have indicated that of those who receive treatment, between 30% (Teh et al. These findings strongly demonstrate the need for providers, consumers, and health care systems to have access to guidelines that provide information about effective treatment options as well as a focused application of dissemination and implementation science. The panel intended to develop a guideline that would be applicable to a broad range of the population, including adolescents through older adult populations. Of note, in reviewing the literature, the panel found that it was unable to separate child research from adolescent research consistently and, therefore, expanded the domain reviewed to include children. In addition, the panel identified the need to include psychotherapeutic interventions. This clinical practice guideline differs in substantive ways from others that are currently available. The systematic review was supplemented by a review of existing reviews as well as meta-analyses to provide more comprehensive coverage of the literature. This, however, led to one of the more significant challenges in the guideline development process. Rather than not address those questions, the panel chose to modify its criteria for systematic reviews and include manuscripts that had used a single rather than dual review process to evaluate articles for inclusion in the review. The consequence is a less methodologically rigorous systematic review because there is an increased risk of bias in the choice of journal articles (Edwards et al. The single reviewer in each of the three meta analyses utilizing single review was panel member and lead author of these published meta analyses, Dr. A fourth goal was to attempt to address the issue of shared versus unique contributions of different psychotherapy models. Most of the psychotherapy treatment literature examines specifically defined models. However, there is a growing body of literature suggesting that shared aspects (common factors [e. An analysis of treatments for major depression found evidence consistent with this (Cuijpers, Driessen, Hollon et al. In addition, the definitions of treatments in articles and reviews varied greatly. Further, in some reviews, treatments were grouped that were arguably not part of the shared family of interventions, reducing panel confidence in consistency across treatment comparisons and judgments about specific contributions of distinct psychotherapies. Thus, the panel was not able to realize this goal but makes recommendations for future research that explicitly addresses the shared components of effective psychotherapy, the necessity of appropriately defining treatments, and newer models of the treatment of depression. Similarly, a fifth goal was to provide appropriate guideline recommendations for underserved populations. These are areas that could contribute to the experience and treatment of depression but for which the panel did not have an adequate literature to address. Finally, arising from these last two goals, the panel was determined to develop a series of recommendations for future research to address the gaps and limitations in the literature that were observed. The panel’s goal is that this guideline serves as a current and functional tool to guide providers, health care systems, and consumers in decision-making regarding treatment and provides investigators guidance on key clinical research questions that are necessary to address so that all can meaningfully improve the ability to treat this pervasive and debilitating disorder. Guideline Purpose and Scope: What the Guideline Does and Does Not Address the purpose of this guideline is to provide recommendations on the treatment of depression in three developmental cohorts: children and adolescents; general population of adults; and older adults. The other reviews were independently conducted by teams of researchers (Cipriani et al. Department of Health and Human Services) strives to improve health care by enhancing access to the relevant evidence bases in collaboration with partners. For individuals in each of the three age cohorts with major depressive disorder, 37 38 persistent depressive disorder, or subsyndromal depression, what is the efficacy and risk of harms of psychotherapy or complementary and alternative medicine treatments For individuals in each of the three age cohorts with major depressive disorder, persistent depressive disorder, or subsyndromal depression, what is the effectiveness and risk of harms of psychotherapy or complementary and alternative medicine treatments in comparison either with one another or with pharmacotherapy For individuals in each of the three age cohorts with major depressive disorder, persistent depressive disorder, or subsyndromal depression, what is the effectiveness and risk of harms of combinations of pharmacotherapy, psychotherapy, or complementary and alternative medicine treatments compared with inactive or active single or combined treatments Are the benefits and risks of these treatment options moderated by subgroup characteristics, including suicidal ideation, treatment-resistant depression, co occurring anxiety disorders, or co-occurring personality disorders Dose (differential beyond current recommended), timing, or duration of treatments for depression. The long-term benefits of treatment for maintenance of recovery and prevention of 42 relapse. The panel had originally proposed to include somatic treatments in the review, but the nature of the search criteria did not adequately capture the literature, and the panel was unable to make recommendations about those interventions. While beyond the scope of this guideline, recent evidence of increasing rates of suicide across a number of cohorts indicates this is a high-priority domain. The panel stresses the importance of this area of practice and the need for more research to contribute to systematic reviews of long-term depression treatment. However, it should be noted that the panel completed its decision making about the recommendations during the 5-year window in which each review was considered current. In constituting the panel, there was an effort to incorporate members who represented a broad range of experiences and expertise in the treatment of depression, including variation in terms of psychotherapy models, populations. While it would not be possible in a panel of this size to represent all constituencies and interests in a truly equitable fashion, the mandate to the panel was to include as broad a perspective as possible when reviewing the literature. While intellectual affiliations were expected, no panel members were to be singularly identified with particular interventions, nor were they to have significant known financial conflicts that would compromise their ability (or appearance thereof) to weigh evidence fairly. Once the panel was formed, all members completed an educational module on conflicts of interest that underscored the importance of identifying and managing any that had either been identified or that might come to light. Conflicts of interest forms were updated annually, and panel members and staff were asked to give more prompt updates if there were any changes in their disclosures that could be relevant to the development of an unbiased guideline. Scoping At its first in-person meeting, the panel began discussion of topic scoping and continued to discuss scope over several subsequent conference calls. The panel also used the Delphi method to complete an outcomes prioritization survey. On this survey panel members rated outcomes from 1 “not important” to 9 “critical” for deciding about what treatment to recommend. Based on the results of this survey, the panel found “response to treatment” (reduction in depressive symptoms) and “serious adverse events” as its two most critical outcomes. Scoping decisions about which populations, interventions, comparators, outcomes, timing, and settings to include as well as the key questions are noted in the Scoping section at the beginning of this document. A meta-analysis is the use of quantitative statistical methods in a systematic review to integrate the results of included studies. Briefly, a systematic review or meta-analysis involves searching a variety of scientific databases using selective search terms to find relevant studies. The individual studies identified by the panel are then assessed to decide whether they meet inclusion criteria as well as assessed for the risk of bias using predefined criteria. For the current guideline, the panel used a systematic review of the literature focused on comparisons of mainly second-generation antidepressant medication and psychotherapy with focus on primary treatment goals. However, due to gaps in the types of treatment comparisons and approaches included in the first review, more reviews were identified and used to address the limitations of the initial review. Gaps found by the panel included an examination of supportive therapy, psychodynamic therapy, subclinical depression, and efficacy of psychological treatments. The panel followed best practices of using reviews current within the past 5 years, and an independent search was not conducted outside of these reviews for additional studies that may not have met inclusion criteria for the reviews. By the time of finalization of the current guideline document, several of the underlying reviews will have crossed the 5-year mark for being considered a current review according to best practices. However, it should be noted that the panel completed its decision-making about the recommendations during the 5-year window in which each review was considered current. The panel used two meta-analyses after determining they were of sufficient quality.

buy generic atenolol 100 mg online

As none of the symptoms are unique to blood pressure 5020 buy 50mg atenolol amex the syndrome arteriographic embolization discount atenolol 50mg with mastercard, patients need to blood pressure medication common buy cheap atenolol 50mg online keep a daily diary of symptoms for at least 2 menstrual cycles to blood pressure chart free printable 100 mg atenolol fast delivery establish the temporal relationship between the onset of symptoms and the premenstrual period and the absence of symptoms or a chronic underlying disorder during the follicular phase (12). The choice of the instrument should be justified and validated in the target population (8). Retrospective reporting is not acceptable as retrospective recall of symptoms is unreliable (27). Various scoring methods compare the average of symptom scores during the premenstrual days with the average of symptom scores postmenses. Methods should be foreseen in the study protocol to assess inter-rater reliability (see 4. Although the lifetime comorbidity between the two disorders is significant, ranging from 30 to 70%, there is consistent evidence to support the distinct nature of each diagnosis. A key feature of depressive disorders is that symptoms are almost always present every day of the cycle. A careful diagnosis based on clearly defined, replicable severity criteria via prospective ratings for two run-in cycles is essential (see sections 4. Therefore cycles within the lower limit of 24 days and an upper limit of 35 days are considered to be within a normal range. The determination of ovulatory cycles is required for pharmacodynamic trials where ovulation-related underlying mechanisms are studied (14). Exclusion criteria Not menstruating, including pregnant 6/14 Any axis I disorder. In case hormonal contraceptives are used before the start of the trial as baseline therapy for contraception (depending on the medication studied), stratified analysis for add-on medication should be pre-specified. Improvement should be documented as the mean difference between the average luteal phase 2 prospectively assessed qualification scores as baseline score and luteal phase ratings of the end-of treatment cycle for each patient after 6 months of treatment (see section 4. The primary endpoint should assess the difference in improvement between treatment groups. The scores of improvement per cycle should also be compared, in addition to the end scores in symptomatology (see 4. Results should be discussed in terms of both clinical relevance and statistical significance. In order to allow an estimate of clinical relevance, improvement should also be expressed as the proportion of responders. Definition of responders should be based on clinical consideration and done prospectively. There is no data-based evidence of superiority of one type of rating scale over another in determining the outcome. However rating scales that combine measurement of affective symptoms, physical and functional impairment on a daily basis should be preferred. The choice of the rating scales should be justified from the test quality criteria (reliability, validity). Important secondary endpoints: Change from baseline in psychological and physical impairment. All assessment tools used should be justified based on psychometric properties (4, 23). Although the assessment of efficacy should be based on prospective self-rating, this should be supplemented by observer-ratings based on structured patient interviews undertaken by the clinician 7/14 and global assessment of symptom severity, improvement and adverse events. Pharmacodynamic data should be obtained depending on the mode of action of the examined substance. There is a list of minimal requirements clearly stated in the Points to consider on application with 1. In case of inclusion of an active control arm, the choice and dose of the comparator should be justified on the basis of placebo-controlled evidence of efficacy of the comparator. Generally a placebo wash-out period to exclude placebo responders is not useful and may impair generalisation of the results. In addition, information of patients screened but not included in the study should be documented. In controlled settings such as clinical trials, some women become anovulatory due to stress. Therefore, especially in treatments not aiming at suppressing ovulation, corpus luteum formation should be monitored before and under therapy. Blinding Special attention should be paid to blinding even though this might be difficult in studies investigating medicinal products which may influence the menstrual bleeding pattern. Data analyses Given the chronicity and cyclicity of the symptoms, the maintenance of therapeutic efficacy should be demonstrated over at least 6 cycles. In order to establish efficacy, placebo-controlled data are needed over at least 6 cycles (2 run-in cycles + 6 treatment cycles), especially since a large placebo effect is expected (9). Intermittent, luteal phase treatment strategies may enhance treatment compliance (see 1. Premenstrual symptoms are identified in adolescents and can begin around the age of 14, or 2 years post-menarche, and persist until menopause (5, 28, 29). There is a need to demonstrate that specific therapeutic strategies have similar beneficial effects in adolescents and it is requested to include adolescents in the development program according to the prevalence in the general population (3). Special ethical considerations and safety concerns in adolescents have to be taken into account. Depending on the substance studied, relevant guidelines with specific safety topics and identified risks should be taken into account. General considerations For reference to the relevant safety guidance, see Section 3. Assessment of adverse events, especially those predicted by the pharmacodynamic properties of the investigational product should be performed using a systematic and planned methodology. All adverse events occurring during the course of clinical trials should be fully documented with separate analysis of adverse drug reactions, drop-outs and patients who died while on therapy. Depending on the substance studied relevant guidelines with specific safety topics should be taken into account. Rebound/Withdrawal phenomena/Dependence When pharmacological treatment is stopped, rebound and/or withdrawal phenomena may occur. Therefore, rebound and/or withdrawal phenomena should be systematically investigated. Animal studies will be needed to investigate the possibility of dependence in new classes of compounds or when there is an indication that dependence may occur. Depending on the results of these studies further studies in humans may be needed. Depending on the mode of action of the examined treatment special attention should be paid to long term effects on endocrinium. Intermittent versus continuous treatment strategies might have different impacts on long-term adverse events (see 1. For new chemical entities, long-term safety data of at least 12 cycles are needed. The symptoms are present in the absence of any pharmacologic therapy, hormone ingestion, or drug or alcohol use. The patients suffer from identifiable dysfunction in social or economic performance. Premenstrual daily fluoxetine for premenstrual disorder: A placebo controlled, clinical trail using computerized diaries. Premenstrual dysphoric disorder: Prevalence, diagnostic considerations, and controversies. Characteristics of placebo responses in medical treatment of premenstrual syndrome. The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Screening of patients for clinical trials of premenstrual syndrome/premenstrual dysphoric disorder: methodological issues. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspective. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies.

Buy generic atenolol 100 mg online. Taking Blood Pressure.

order 100 mg atenolol fast delivery

Patients gain insight into and work through such conflicts through exploration of their feelings along with interpretations offered by his/her therapist arrhythmia pac atenolol 50 mg otc. For patients with suspected depression hypertension cardiovascular disease discount atenolol 100mg free shipping, we recommend an [41] assessment for acute safety risks blood pressure very low cheap atenolol 100 mg without prescription. For patients with suspected depression prehypertension hypertension stage 1 generic 50mg atenolol amex, we recommend an [45] appropriate diagnostic evaluation that includes a determination of I Not Reviewed, Strong For functional status, medical history, past treatment history, and relevant Additional References: Amended family history. The strength of recommendations were rated as follows: A a strong recommendation that the clinicians provide the intervention to eligible patients; B a recommendation that clinicians provide (the service) to eligible patients; C no recommendation for or against the routine provision of the intervention is made; D recommendation is made against routinely providing the intervention; I the conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention. For new recommendations, developed by the 2015 guideline Work Group, the literature cited corresponds directly to the 2015 evidence review. For these “modified” recommendations, the evidence column indicates “additional evidence, ” which can refer to either 1) studies that support the recommendation and which were identified through the 2015 evidence review, or 2) relevant studies that support the recommendation, but which were not systematically identified through a literature review. We recommend that treatment planning include patient education about the condition and treatment options, including risks and [71] Not Reviewed, benefits. The individualized treatment plan should be developed using B, I Additional References: Strong For Amended shared decision-making principles, and should define the provider, [72] patient, and support network’s roles. In patients who have demonstrated partial or no response to initial [90, 91, 94, 95, 97] pharmacotherapy monotherapy (maximized) after a minimum of four Reviewed, New to six weeks of treatment, we recommend switching to another None Strong For Additional References: replaced monotherapy (medication or psychotherapy) or augmenting with a second medication or psychotherapy. For patients who select psychotherapy as a treatment option, we Reviewed, New suggest offering individual or group format based on patient B Weak For Additional References: replaced preference. After initiation of therapy or a change in treatment, we recommend [51-53] monitoring patients at least monthly until the patient achieves Reviewed, Amended remission. At minimum, assessments should include a measure of C, B Strong For Additional References: symptoms, adherence to medication and psychotherapy, and emergence of adverse effects. In patients at high risk for recurrent depressive episodes (see Reviewed, New Discussion) and who are treated with pharmacotherapy, we B, C [115, 116, 120] Strong For replaced recommend offering maintenance pharmacotherapy for at least 12 months and possibly indefinitely. Reviewed, New the evidence does not support recommending a specific evidence B, A, A, replaced [123-125] Strong For based psychotherapy over another. Patient B, A, A, Reviewed, New preference and the additional safety risks of pharmacotherapy should [126-128] Strong For C, A, B replaced be considered when making this decision. Identify patients who are depressed Caution should be used in screening patients older than Not A and are no longer engaged in 4 75 years since screening instruments may not perform as C Reviewed, treatment. The strength of recommendations were rated as follows: A= a strong recommendation that the clinicians provide the intervention to eligible patients; B= a recommendation that clinicians provide (the service) to eligible patients; C= no recommendation for or against the routine provision of the intervention is made; D= recommendation is made against routinely providing the intervention; I= the conclusion is that the evidence is insufficient to recommend for or against routinely providing the intervention. Deleted To identify women who are Not In the postpartum period, recommended screening is A depressed during pregnancy or in the 3 C Reviewed, typically at 4 to 6 weeks and 3 to 4 months. Deleted A referral to emergency services and/or consultation with a mental health professional is indicated for patients presenting with any of the following unstable conditions: a. Substance withdrawal or intoxication Any patient with suicidal ideation or attempts Not Identify patients who are at high risk B 2 necessitating psychiatric hospitalization should be None Reviewed, of harm to self or others. One recommended line of questioning uses the following (modified from Hirschfeld & Russell, 1997): a. Risk of violence towards others should be assessed by asking directly whether or not the patient has thoughts of harming anyone: Identify patients who pose a threat a. Assess whether the patient has an active plan and Not C to self or others and initiate 2 method/means. Patients who have longstanding psychotic illness and who Identify patients who have acute or Not are able to attend to present circumstances without C chronic psychosis and treat 3 None Reviewed, responding to their psychosis, may be evaluated and treated accordingly. Ensure that appropriate care, protocols and regulatory/policy Local, state, and federal regulations/mandates as well as Not mandates are followed during D 1 guidelines should be followed if the patient represents a None Reviewed, diagnosis and stabilization of the risk to self or others. Ensure that appropriate care, protocols and regulatory/policy mandates are Not Patient care management plans must reflect the realities D followed during diagnosis and 3 None Reviewed, of local resources, staffing, and transportation. Complete a thorough medical and Once the patient is stable, the clinical assessment should mental health history and examination Not be completed by the primary care provider, including a E to develop an appropriate clinical 1 I Reviewed, Recommendation 4 relevant history, physical examination, and laboratory understanding of the patient’s Amended tests as indicated. During the past few weeks, have any physical or mental health history and emotional problems interfered with your typical Not examination to develop an daily activities If positive, areas for brief inquiry include: job, pleasurable hobbies, social activities, and important personal relationships. Review of psychiatric, marital, family, and military service history, past physical or sexual abuse, and medication or substance use. Treatment for any prior mental health problems, past psychiatric hospitalizations, or inability to function in usual life roles. Loss of significant relationship, primary support system, or economic status viii. Protracted care-giving role for a family member with a chronic, disabling condition x. Review of medications, including prescription drugs and over-the-counter drugs (herbals, nutritionals, vitamins, and body building supplements). Deleted Identify patients who may be Consideration should also be given to herbals, Not F experiencing depressed symptoms as 2 nutritionals, vitamins, and body building supplements, None Reviewed, a side effect of medication. Trauma Identify patients who may be Simultaneous treatment is often required for both the Not experiencing depressed symptoms as F 2 medical problem and psychiatric symptoms and can lead None Reviewed, a result of an underlying medical to overall improvement in function. Patients presenting to primary care with evidence or suspicion of co-occurring psychiatric disorders should be offered referral to mental health specialty for evaluation and treatment. Conditions that should prompt the primary care provider to consider referral include: a. Extreme weight loss suggestive of anorexia nervosa Determine whether other psychiatric Not b. Extensive history of childhood abuse, unstable or G conditions are present and may 1 None Reviewed, broken relationships, or criminal behavior starting complicate treatment. Deleted before or during adolescence, that is suggestive of a personality disorder c. Frequent and disabling nightmares or flashbacks suggestive of post-traumatic stress disorder. Patient presenting with unexplained physical symptoms Determine whether other psychiatric Not and depression should be offered referral to a mental G conditions are present and may 2 None Reviewed, health specialist as these may represent a somatoform complicate treatment. The possible existence of bipolar disorder should be Not Determine if the patient has bipolar G 1 assessed in patients presenting with depressive symptoms, None Reviewed, disorder. Deleted Not Determine if the patient has bipolar Patients suspected to have bipolar disorder should be G 2 None Reviewed, disorder. Deleted Patients presenting with unexplained physical symptoms Not Determine if the patient has other G 1 and depression should be offered referral to a mental health None Reviewed, somatoform disorders. Build a trust relationship with the patient None Reviewed, somatoform disorders. Carefully explain the reason for referral before and Deleted after it is recommended c. The diagnosis of dysthymia may be considered in patients who experienced a two-year period during which, for most days, the individual experiences depressed mood for more than half the of the day, along with at least two of the following symptoms: Not Identify patients with a diagnosis of a. Increased or decreased appetite H 1 None Reviewed, dysthymia and treat accordingly. Primary care providers may consider antidepressant pharmacotherapy or a combined course of pharmacotherapy and psychotherapy if the patient is Identify patients with a diagnosis of Reviewed, H 3 diagnosed with dysthymia, though the evidence suggests None dysthymia and treat accordingly. Deleted that the benefits of psychotherapy, and possibly pharmacotherapy, are lower than those found in treatment of major depression. Including the patient in decisions Not Patients should receive information that is reasonable for K about their medical care may 1 None Reviewed, them about their treatment options. Deleted Including the patient in decisions Not Patients should be informed about the risks and benefits K about their medical care may 2 None Reviewed, of each treatment option. Deleted Including the patient in decisions Not Patients should be assessed for their understanding of K about their medical care may 3 None Reviewed, the ramifications of their choice. Failure to respond to adequate depression treatment or otherwise complicating treatment b. A co-existing mental health disorder that significantly Appropriately refer patients with complicates treatment. A co-existing medical condition that significantly complicates the treatment planning for depression d. Personal or family history of suicide attempts or suicidal ideas necessitating psychiatric hospitalization f. A past depressive episode involving severe loss of functioning or other life threatening consequences. The primary care provider should consider consultation with mental health specialists in the following circumstances: a. Need for, or patient request for, psychotherapy or Deleted combination of both medication and psychotherapy.

purchase atenolol 100mg on line

Violence must be viewed not as an individual problem blood pressure chart homeostasis discount 50 mg atenolol, but a symptom of the breakdown of the social order and therefore a problem for the group arrhythmia and murmur cheap atenolol 100mg online. Every act of violence blood pressure 7843 buy atenolol 100mg mastercard, be it physical blood pressure zippy 50 mg atenolol with visa, sexual, emotional or verbal, must be analyzed, understood, and addressed as a problem of and for the entire community to resolve – nonviolently. Sexual assault is one of the most basic violations one human being can inflict on another. For far too long in our social history, rape has been a way of exerting power over others. In personal relationships, it is a way for men to exert the fact of their physical dominance over women and other men. In the family the sexual assault of children is a way for adults to use children as convenient “poison containers” for all the unexpressed and unresolved conflicts in their own lives – because they have the power to do so. Sexual assault is about a fundamental abuse of power and arguably is such a prevalent form of violation because the norms of our society continue to justify and support abusive power in all of its forms. Sexual Assault of Young Children as Reported to Law Enforcement: Victim, Incident and Offender Characteristics, July 2000. Child Maltreatment 1998: Reports from the States to the National Child Abuse and Neglect Data System. The Prevalence and Consequences of Child Victimization: Summary of a Research Study by Dean Kilpatrick, Ph. Improving the Health of Adolescent Girls: Policy Report of the Commonwealth Fund Commission on Women’s Health. Sexual abuse of boys: definition, prevalence, correlates, sequelae, and management. Rape related pregnancy: estimates and descriptive characteristics from a national sample of women. Department of Justice, Bureau of Justice Statistics, Characteristics of Crime, October 26, 2000. Psychiatric Clinics Of North America:Treatment of Victims of Sexual Abuse, 1989; 12:389 411). Neurodevelopment and the psychobiological roots of post traumatic stress disorder. The body keeps the score: Approaches to the psychobiology of posttraumatic stress disorder. Traumatic Stress: the Effects of Overwhelming Experience on Mind, Body and Society. Brady (Eds), Handbook of Psychological Injuries: Evaluation, Treatment and Compensable Damages. Cognitive and behavioral sequelae of combat: conceptualization and implications for treatment. Delayed memories of child abuse: Part I: An overview of research findings on forgetting, remembering, and corroborating trauma. Memory, Trauma Treatment, and the Law: An Essential Reference on Memory for Clinicians, Researchers, Attorneys, and Judges. The psychobiology of traumatic memory: Clinical implications of neuroimaging studies. Neurodevelopment and the neurophysiology of trauma I: Conceptual considerations for clinical work with maltreated children. The Advisor: American Professional Society on the Abuse of Children, 1993; 6, 14 18 58 Schwarz, E. Emotional numbing: a possible endorphin mediated phenomenon associated with post traumatic stress disorders and other allied psychopathologic states. An unusual reaction to opioid blockade with naltrexone in a case of post traumatic stress disorder. The psychobiology of the trauma response: Hyperarousal, constriction, and addiction to traumatic reexposure. Borderline personality disorder and laboratory induced cold pressor pain: evidence of stress induced analgesia. Stress versus traumatic stress: From acute homeostatic reactions to chronic psychopathology. In Traumatic Stress: the Effects of Overwhelming Experience on Mind, Body, and Society. Factors Associated with Sexual Behavior Problems in Young Sexually Abused Children. Prevalence of post traumatic stress disorder and other psychiatric diagnoses in three groups of abused children (sexual, physical, and both). Sexual abuse and adolescent maladjustment: differences between male and female victims. Epidemiology of posttraumatic stress disorder among victims of intentional violence: A review of the literature. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Panic disorder versus panic disorder with major depression; defining and understanding differences in psychiatric morbidity. Current and lifetime psychiatric disorders among veterans with war zone related posttraumatic stress disorder. Prevalence of somatoform disorders in a large sample of patients with anxiety disorders. Personality disorders in patients with panic disorder: association with childhood anxiety disorders, early trauma, comorbidity, and chronicity. European Archives of Psychiatry and Clinical Neuroscience, 1992; 242(2 3): 135 141. Sexual and physical abuse history in gastroenterology practice: how types of abuse impact health status. Long term correlates of child sexual abuse: theory and review of the empirical literature. Paper presented as 1994 Eli Lilly Lecture to the Royal College of Psychiatrists, London, February 2, 1994. A clinical profile of women with posttraumatic stress disorder and substance dependence. A model for the treatment of trauma related syndromes among chemically dependent inpatient women. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Childhood trauma, the neurobiology of adaptation and use dependent development of the brain: How “states” become “traits”. Predictors of cortisol and 3 methoxy 4 hydroxyphenylglycol responses in the acute aftermath of rape. The relationship between symptoms of post traumatic stress disorder and pain, affective disturbance and disability among patients with accident and non accident related pain. Dissociation, somatization, substance abuse, and coping in women with chronic pelvic pain. Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome. Correlation between sexual abuse and somatization in women with somatic and nonsomatic chronic pelvic pain. Influence of life stress on immunological reactivity to mild psychological stress. Health psychology: psychological factors and physical disease from the perspective of human psychoneuroimmunology. Cellular immunity in depressed, conduct disorder, and normal adolescents: role of adverse life events. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. Prevalence of post traumatic stress disorder among gynecological patients with a history of sexual and physical abuse.


  • http://meak.org/science/Jennifer-Lynn-Gars/purchase-fml-forte-no-rx/
  • https://missionhealth.org/wp-content/uploads/2018/03/2016_cancer_care_annual_report_final.pdf
  • http://meak.org/science/Jennifer-Lynn-Gars/order-anacin-no-rx/
  • https://www.issuelab.org/resources/26706/26706.pdf